1. Japan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
JMS Co., Ltd.

JMS Co., Ltd.

TTSE:7702
449.00
JPY
-3.00
(-0.66%)
10.43BMarket Cap
Nov 06Next Earn
JMS Co., Ltd.
TSE:7702
(Tokyo Stock Exchange)

Recent

price

449.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
2,112.24
2,170.4
2,259.33
2,208.83
2,272.4
2,364.59
2,280.39
2,319.46
2,382.04
2,402.14
2,358.97
2,381.25
2,607.66
2,668.18
2,846.47
2,685.22
- -
Revenue per Share
59.82
43.65
58.8
8.49
5.7
30.93
48.5
25.89
47.59
81.08
71.12
33.81
11.5
-1.47
3.63
-31.93
- -
Basic EPS, GAAP
47.96
-45.65
-34.63
-144.11
-29.2
-75.08
-6.85
-11.08
56.04
10.79
19.71
46.59
-43.82
20.35
-64.19
-43.84
- -
Free Cash Flow per Basic Share
14.97
15.94
15.89
15.99
16
16
19.9
16
16.08
16
17.49
16.95
16.98
16.96
16.98
16.96
- -
Dividend per Share
1,143.51
1,146.22
1,205.2
1,252.02
1,288.82
1,263.35
1,269.31
1,289.53
1,303.04
1,326.12
1,426.72
1,512.69
1,575.93
1,657.22
1,666.44
1,701.15
- -
Book Value per Share
1,114.46
1,113.93
1,175.11
1,222.08
1,263.1
1,242.5
1,250.92
1,271.56
1,282.4
1,304.06
1,398.39
1,470.33
1,541.28
1,616.58
1,627.96
1,661.12
- -
Tangible Book Value per Share
22
22
22
24
24
24
24
24
24
24
24
24
24
24
25
25
25
Basic Weighted Avg Shares
45,587
46,836
49,068
53,860
55,401
57,636
55,574
56,520
58,059
58,569
57,578
58,169
63,740
65,292
69,749
65,845
- -
Sales/Revenue/Turnover
3.75
2.25
3.25
1.67
0.69
2.47
1.99
1.02
2.52
3.95
3.69
1.69
1.14
-0.41
1.25
0.58
- -
Operating Margin (%)
2,605
2,574
1,715
2,249
2,522
2,691
2,972
3,059
3,044
3,160
3,242
3,359
3,593
3,714
3,888
3,833
- -
Depreciation Expense
1,291
942
1,277
207
139
754
1,182
631
1,160
1,977
1,736
826
281
-36
89
-783
- -
Net Income, GAAP
15.65
26.48
29.96
77.88
63.61
36.02
- -
15
21.49
22.56
21.6
24.28
57.74
131.72
98.75
- -
- -
Effective Tax Rate (%)
2.83
2.01
2.6
0.38
0.25
1.31
2.13
1.12
2
3.38
3.02
1.42
0.44
-0.06
0.13
-1.19
- -
Profit Margin (%)
12,132
12,098
13,158
12,424
13,822
13,461
15,495
16,116
15,085
15,193
16,438
17,195
19,826
18,736
20,144
20,703
- -
Working Capital
2,485
2,610
2,393
2,632
6,374
10,457
11,787
12,541
11,088
10,623
9,831
10,364
11,658
12,319
13,175
13,192
- -
LT Debt
24,723
25,184
29,462
30,619
31,530
30,907
31,061
31,549
31,899
32,470
34,992
37,091
38,699
40,746
40,925
41,790
- -
Total Equity
4.47
2.38
3.21
0.52
0.33
1.98
- -
0.97
2.24
3.49
3.17
1.35
0.53
0.13
0.02
- -
- -
Return on Invested Capital (%)
4.28
3.09
3.86
0.56
0.41
1.74
- -
1.48
2.55
4.16
3.58
1.75
0.65
-0.15
0.26
- -
- -
Return on Capital (%)
5.27
3.78
4.68
0.69
0.45
2.42
3.83
2.02
3.67
6.17
5.17
2.3
0.74
-0.09
0.22
-1.9
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
11,949
14,814
- -
LT Borrowings
13,895
12,005
- -
LT Finance Leases
- -
1,187
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
25
25
25
Market Capitalization
10,794
10,425
10,916

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
48,197
47,385
- -
Cash, Cash Equivalents & STI
8,129
7,721
- -
Accounts Receivable, Net
17,749
18,654
- -
Inventories
20,773
20,203
- -
Total Current Liabilities
25,499
26,682
- -
Payables & Accruals
- -
- -
- -
ST Debt
11,949
14,814
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.09%
3.64%
2.11%
Free Cash Flow
-128.45%
-130.31%
-31.66%
Net Income, GAAP
-140.6%
-311.64%
-979.78%
Sales/Revenue/Turnover
1.43%
2.85%
-5.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
69,749
2026
- -
- -
- -
- -
65,845
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
3.63
2026
- -
- -
- -
- -
-31.93
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
16.98
2026
- -
- -
- -
- -
16.96
2027
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
JMS Co., Ltd. manufactures, sells, exports, and imports medical devices and pharmaceuticals primarily focused on infusion and transfusion therapy, dialysis, cardiovascular treatments, blood management, and cell therapy. The company, founded in 1965 and headquartered in Hiroshima, Japan, operates globally through subsidiaries and affiliates in North America, Europe, Asia including China, South Korea, Singapore, Indonesia, and the Philippines; its product portfolio encompasses infusion and nutrition solutions such as needless access ports, closed drug mixing and infusion systems including NEO SHIELD for oncology, infusion pumps, and oral/enteral nutrition systems; dialysis solutions featuring AV fistula needles, peritoneal dialysis solutions, automated peritoneal dialysis equipment like PD-Relaxa, hemodialysis machines including the recently launched JMS Single Patient Dialysis Machine SD-X01, and prefilled syringes; cardiovascular products such as membrane oxygenators and cardiopulmonary blood tubing sets; blood management items including blood bags, serum collection sets, and leukocyte reduction filters; alongside general medical supplies, oncology therapy devices, and other equipment for hospital care and logistics. In recent developments, JMS acquired JMS Transfusion Technology (Zhangjiagang) Co., Ltd. from Asahi Kasei Medical in November 2023 to bolster its leukocyte reduction filter business and global blood management supply chain targeting Africa, the Middle East, Asia, and Oceania; established JMS TEIJIN Home Medical Care Ltd. joint venture with Teijin Pharma in October 2024 for peritoneal dialysis and home therapy expansion starting April 2025; launched the NEO SHIELD closed drug transfer system adopted by JAXA for research and gaining oncology market share; introduced the SD-X01 dialysis machine in February 2025; and earned Health Management Excellence Corporation certification for the third consecutive year in March 2025 while advancing its Medium-Term Management Plan 2027 emphasizing profit structure reform, globalization, and sustainability with targets of JPY 2.5 billion operating profit and over 3.5% ROIC by FY2027.